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evaluated by Subjective Global Assessment (SGA). The
comorbidity of each patient was stratiﬁed by Index of Co-
Existent Disease (ICED). The MOS-Short Form 36 ques-
tionnaire was ﬁlled at home by patients to evaluate their
HRQoL. The eight multi-items scales, General Health
(GH), Role Physical (RP), Physical Function (PF), Role
Emotional (RE), Social Function (SF), Bodily Pain (BP),
Emotional Well-Being (EW-B), Energy/Fatigue (EF) were
summarized into two scores: Physical Component Score
(PCS), Mental Component Score (MCS).The scores were
expressed as median value. U-Mann Withney test was
used to compare the scores of the eight domains measured
by SF-36. QoL correlates were investigated with a series
of logistic regression analyses, where questionnaire
scores, dychotomised using the median value as cut-off,
were the depend variables. Results are thus expressed in
terms of Odds Ratio. RESULTS: The patients on CAPD
had a better, but not statistically signiﬁcant, self-percep-
tion of GH, SFand BP. The scores of the other domains
were signiﬁcantly better in CAPD than in CHD patients
(RP: 37vs37p < 0.02; PF: 75vs20p < 0.001; RE: 83vs20p
< 0.0002; EWB: 50vs45p < 0.0001; EF: 64vs52p < 0.01;
PCS: 40vs36p < 0.05; MCS: 43vs39 p < 0.05). Among
clinical correlates, female sex (OR: 3.34–95% CI:
1.12–9.03 p < 0.002), age > 58 years (OR: 3.81–95% 
CI -1.33–10.9 p < 0.01), SGA ≥ 1 (OR: 5.6–95% CI:
1.8–17.5 p < 0.001) high comorbidity (OR: 2.25–95%
CI: 1.5–13.4 p < 0.005) were signiﬁcantly associated 
to lower values of PCS. MCS was lower in patients 
with diuresis <500ml/die. CONCLUSIONS: Patients on
CAPD had a better self-perception of QoL until signiﬁ-
cant diuresis was manteined.
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OBJECTIVE: The degree of severity of the undesirable
mictional problems caused by BPH is assessed according
to the scores obtained in the acknowledged and validated
IPSS questionnaire. METHOD: In accordance with 
the WHO recommendations, the IPSS was proposed to
patients (n = 189) in the form of a self-questionnaire with
the aim of analyzing the obstruction and irritation scores
for the patients suffering from a recently diagnosed BPH
and treated with Serenoa Repens. RESULTS: The IPSS
obstruction score was respectively 6.7 (3.8) and 5.9 (3.5)
upon patient inclusion and after six months. This noted
difference is statistically signiﬁcant (p < 0.0001). The IPSS
irritation score was respectively 5.5 (2.6) and 4.5 (2.3)
upon patient inclusion and after six months. This dif-
ference is here statistically signiﬁcant with p < 0.0001.
CONCLUSION: Treatment by ﬁrst intention with
Serenoa Repens thus showed a signiﬁcant improvement
as demonstrated by both the obstruction and irritation
scores.
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OBJECTIVE: Undesirable mictional problems caused by
a BPH have been found in 20 to 25% of the male popu-
lation over 50 years old. This condition can thus be 
considered as a public health problem that offers many
aspects in terms of diagnosis, therapeutics or economics.
METHOD: Within the framework of a follow-up cohort
study, a patient population suffering from a recently diag-
nosed BPH and treated with Serenoa repens (n = 158) was
asked to ﬁll in questionnaires SF12 and SPI upon inclu-
sion and 6 months later. RESULTS: When looking at the
SF-12, the results were organized in 2 types of scores: 
psychological (MCS-12) and physical (PCS-12). The SF12
scores upon patient inclusion were: PCS-12 = 41.7 and
MCS-12 = 46.5. The SF12 scores after 6 months were:
PCS-12 = 45.4 and MCS-12 = 46.9. These results bring
out a signiﬁcant improvement in the physical dimension
of the SF-12 (p < 0.0001). The SPI score upon patient
inclusion was 12.6 and reached 10.8 after 6 months of
treatment. This improvement is statistically signiﬁcant 
(p < 0.0001). CONCLUSION: Treatment by ﬁrst inten-
tion with Serenoa repens thus showed a signiﬁcant
improvement as demonstrated by the 2 validated scales,
SF12 and SPI.
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OBJECTIVE: Undesirable mictional problems caused by
a BPH—benign prostatic hypertrophy—have been found
in 20 to 25% of the male population over 50 years old.
This condition can thus be considered as a public health
problem that offers many aspects in terms of diagnosis,
therapeutics or economics. METHOD: Using a follow-up
cohort study, we isolated two groups presenting a recently
diagnosed BPH: the ﬁrst patient population was kept
under medical supervision (n = 101) versus a second
patient population undergoing treatment with Serenoa
Repens (n = 112). RESULTS: For the patients under
medical supervision, the IPSS score was respectively 11.8
(5.7) and 10.9 (6.7) upon patient inclusion and after 6
months. This difference is not statistically signiﬁcant.
However, for the patients treated with Serenoa Repens,
